Grazia Aleppo, United States of America
Northwestern University Feinberg School of MedicineAuthor Of 3 Presentations
Q&A (ID 1115)
Are technology guidelines outpacing CGM adoption for type 2 diabetes in clinical practice? (ID 1113)
OP084 - VIRTUAL DIABETES SPECIALTY CARE – INDIVIDUALIZED TELEMEDICINE AND TECHNOLOGY SUPPORT (ID 336)
Abstract
Background and Aims
The feasibility and efficacy of establishing a comprehensive care virtual diabetes clinic model including initiation and support for continuous glucose monitor (CGM) use was examined.
Methods
234 adults ≥18 years old with type 1 diabetes (T1D; N=160) or type 2 diabetes (T2D, N=74) using basal-bolus insulin (73 pump, 161 multiple daily insulin injections) were assigned a certified diabetes care and education specialist to provide telehealth support including remote CGM training. Participants not using a Dexcom G6 CGM (N=187) at enrollment were provided a Dexcom G6; current users (N=47) continued use. Participants were followed for 6 months to assess CGM use, glycemic and quality of life outcomes.
Results
Mean HbA1c reduction from baseline to 6 months was 0.6% (P<0.001)(T1D) and 1.0% (P<0.001)(T2D). Mean glucose decreased from 183mg/dL to 165mg/dL (T1D) and 199mg/dL to 166mg/dL (T2D). Over 6 months, mean% time in range 70-180 mg/dL increased from 50% at baseline to 61% (T1D) and 48% to 66% (T2D); median use of CGM was 96% (T1D) and 94% (T2D). Glycemic outcomes improvements were observed in both current CGM users and those initiating CGM. Surveys indicated substantial benefit of CGM with reduced diabetes distress, and increased glucose monitoring satisfaction.
Conclusions
Virtual clinic support was successful in achieving sustained CGM use and improved glycemic and quality of life outcomes. This approach could substantially increase CGM adoption by people with diabetes using insulin and improve outcomes among current CGM users by eliminating barriers such as geography and access to specialty care.
Presenter of 3 Presentations
Q&A (ID 1115)
Are technology guidelines outpacing CGM adoption for type 2 diabetes in clinical practice? (ID 1113)
OP084 - VIRTUAL DIABETES SPECIALTY CARE – INDIVIDUALIZED TELEMEDICINE AND TECHNOLOGY SUPPORT (ID 336)
Abstract
Background and Aims
The feasibility and efficacy of establishing a comprehensive care virtual diabetes clinic model including initiation and support for continuous glucose monitor (CGM) use was examined.
Methods
234 adults ≥18 years old with type 1 diabetes (T1D; N=160) or type 2 diabetes (T2D, N=74) using basal-bolus insulin (73 pump, 161 multiple daily insulin injections) were assigned a certified diabetes care and education specialist to provide telehealth support including remote CGM training. Participants not using a Dexcom G6 CGM (N=187) at enrollment were provided a Dexcom G6; current users (N=47) continued use. Participants were followed for 6 months to assess CGM use, glycemic and quality of life outcomes.
Results
Mean HbA1c reduction from baseline to 6 months was 0.6% (P<0.001)(T1D) and 1.0% (P<0.001)(T2D). Mean glucose decreased from 183mg/dL to 165mg/dL (T1D) and 199mg/dL to 166mg/dL (T2D). Over 6 months, mean% time in range 70-180 mg/dL increased from 50% at baseline to 61% (T1D) and 48% to 66% (T2D); median use of CGM was 96% (T1D) and 94% (T2D). Glycemic outcomes improvements were observed in both current CGM users and those initiating CGM. Surveys indicated substantial benefit of CGM with reduced diabetes distress, and increased glucose monitoring satisfaction.
Conclusions
Virtual clinic support was successful in achieving sustained CGM use and improved glycemic and quality of life outcomes. This approach could substantially increase CGM adoption by people with diabetes using insulin and improve outcomes among current CGM users by eliminating barriers such as geography and access to specialty care.